Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

OncoSec Medical is an advanced-stage biomedical company that focuses on the development of novel therapeutic oncology products. The company's core technology is an untapped delivery system, that applies short electric impulses to a tumor, causing transient pores to open in the cellular membrane, allowing therapeutic agents to more readily enter cancer cells. This process is known as OMS electroporation. Using OMS electroporation in tandem with chemotherapeutic or biologic agents can selectively and effectively treat cancerous tumors and cells embedded among predominantly healthy tissue.

Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Ariana Pharma is a premium provider of advanced, clinical and biomarker data analytics technology. Ariana’s unique technology exhaustively mines data, increasing the success of both clinical trials and multi-parametric diagnostic tools. Their team of biostatisticians, software developers, clinical experts and business developers works hard to save sponsors both time and money. Ariana analyzes multi-parametric data (biochemical, genomic, proteomic, genetic, metabolic, patient characteristics, etc.) to identify patient responders and reduce clinical and drug development risk. Their clincial data analysis service optimizes clinical trial inclusion/exclusion criteria, and minimizes the risk of adverse events, thus reducing recruitment costs while detecting hidden signals and working with incomplete data sets. Overall, they have a flawless track record of maximizing the value of clinical assets. Their biomarker data analysis service also helps you develop robust biomarker signatures and find the best combinations in your data. They deliver the actionable information you need to support your development processes: they integrate and analyze multi-parametric data to provide you with the most relevant combinations of biomarkers and patient characteristics. Their methodology is implemented via their innovative software platform KEM® (Knowledge Extraction and Management), a system uniquely conceived and developed here at Ariana Pharma, with strong collaboration with academic (Institut Pasteur, CNRS) and industry groups (GSK, Novartis, Pfizer, etc.). KEM® is an effective technology used across the life science industry, including organizations such as the FDA, that can accelerate the discovery and development process.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Sysmex Corp. engages in the healthcare business. It develops, manufactures, sells, exports, and imports diagnostic instruments, reagents. and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing. It operates through the following geographical segments: Japan, Americas, Europe, Middle East, and Africa (EMEA), China, and Asia Pacific. The company was founded by Taro Nakatani on February 20, 1968 and is headquartered in Kobe, Japan.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Bio-Rad Innovations SAS engages in the development and production of chemicals used in biochemical, pharmaceutical and other life science research applications. The company is headquartered in Paris, France.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of pharmaceutical products and health foods. It operates through the following segments: Pharmaceuticals, Information Service, and Others. The Pharmaceuticals segment researches, develops, manufactures, and markets drugs, which are used in the fields of urology, dialysis, women's health, ophthalmology, endocrinology and metabolism. The Information Service segment offers information services to use in IT and capital investment. The Others segment includes merchandise sales and construction contractors. The company was founded on August 9, 1946 and is headquartered in Matsumoto, Japan.